Ali Muhammedoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Muhammedoğlu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Merve Tokoçin
Department of General Surgery, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul 34100, Turkey
2 shared publications - Ahmet Akbaş
Department of General Surgery, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Türkiye
1 shared publication - Ahmet Bilici
Department of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul 34214, Türkiye
1 shared publication - Ahu Senem Demiröz
Department of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey
1 shared publication - Anıl Yıldız
Department of Medical Oncology, Basaksehir Cam ve Sakura City Hospital, 34480 Istanbul, Türkiye
1 shared publication - Atilla Celik
Department of General Surgery, University of Health Sciences Türkiye, Istanbul Bacılar Training and Research Hospital, Istanbul 34100, Turkey
1 shared publication
Latest Publications
- Open Access
- 8 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4429
Association of Pretreatment Serum Albumin and Systemic Inflammatory Markers with Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer
Background: Pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer is influenced by multiple tumor- and host-related factors, and readily available pretreatment biomarkers of response are still limited. This study aimed to evaluate the association between pretreatment systemic inflammatory and nutritional parameters and pCR assessed by the Miller–Payne grading system, with a specific focus on the independent predictive value of pretreatment serum albumin compared with established inflammatory ratios. Methods: A total of 226 patients with breast carcinoma who received NACT between May 2017 and September 2023 were retrospectively evaluated. Pretreatment laboratory parameters—including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), serum albumin, and the CRP/albumin ratio (CAR)—were recorded. Pathological response was assessed using the Miller–Payne grading system by two breast pathologists blinded to laboratory data. Univariable and multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed, complemented by bootstrap validation of the optimal cut-off, a sensitivity analysis using the contemporary ypT0/is ypN0 definition of pCR, and a subgroup analysis by molecular subtype. Results: pCR was observed in 41 patients (18.1%). Pretreatment serum albumin levels were significantly lower in responders than in non-responders (p = 0.027), whereas NLR, PLR, CRP, and CAR were not significantly associated with response. In multivariable analysis, pretreatment serum albumin, Ki-67, and HER2 status emerged as independent predictors of pCR. ROC analysis demonstrated moderate discriminatory ability for albumin (AUC = 0.64); the optimal cut-off was 4.22 g/dL (bootstrap 95% CI 3.50–4.53 g/dL), with values below this threshold associated with a higher likelihood of pCR. The association between low pretreatment albumin and pCR was particularly pronounced in the triple-negative subgroup (3.30 vs. 4.02 g/dL, p = 0.027). The albumin signal remained significant under the stricter ypT0/is ypN0 definition of pCR in univariable analysis (OR 0.47, p = 0.045). Conclusions: Pretreatment serum albumin, independent of systemic inflammatory ratios, is associated with pCR to NACT in breast cancer and may serve as a candidate biomarker for pretreatment risk stratification, particularly when interpreted alongside established tumor-related predictors such as Ki-67 and HER2 status. The association appears especially relevant in the triple-negative subgroup, suggesting that patients with TNBC and low pretreatment serum albumin may warrant heightened multidisciplinary attention during NACT. Validation in larger, prospective, multicenter cohorts is needed before routine clinical implementation.
- 8 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4429
Open AccessAssociation of Pretreatment Serum Albumin and Systemic Inflammatory Markers with Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer
Background: Pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer is influenced by multiple tumor- and host-related factors, and readily available pretreatment biomarkers of response are still limited. This study aimed to evaluate the association between pretreatment systemic inflammatory and nutritional parameters and pCR assessed by the Miller–Payne grading system, with a specific focus on the independent predictive value of pretreatment serum albumin compared with established inflammatory ratios. Methods: A total of 226 patients with breast carcinoma who received NACT between May 2017 and September 2023 were retrospectively evaluated. Pretreatment laboratory parameters—including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), serum albumin, and the CRP/albumin ratio (CAR)—were recorded. Pathological response was assessed using the Miller–Payne grading system by two breast pathologists blinded to laboratory data. Univariable and multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed, complemented by bootstrap validation of the optimal cut-off, a sensitivity analysis using the contemporary ypT0/is ypN0 definition of pCR, and a subgroup analysis by molecular subtype. Results: pCR was observed in 41 patients (18.1%). Pretreatment serum albumin levels were significantly lower in responders than in non-responders (p = 0.027), whereas NLR, PLR, CRP, and CAR were not significantly associated with response. In multivariable analysis, pretreatment serum albumin, Ki-67, and HER2 status emerged as independent predictors of pCR. ROC analysis demonstrated moderate discriminatory ability for albumin (AUC = 0.64); the optimal cut-off was 4.22 g/dL (bootstrap 95% CI 3.50–4.53 g/dL), with values below this threshold associated with a higher likelihood of pCR. The association between low pretreatment albumin and pCR was particularly pronounced in the triple-negative subgroup (3.30 vs. 4.02 g/dL, p = 0.027). The albumin signal remained significant under the stricter ypT0/is ypN0 definition of pCR in univariable analysis (OR 0.47, p = 0.045). Conclusions: Pretreatment serum albumin, independent of systemic inflammatory ratios, is associated with pCR to NACT in breast cancer and may serve as a candidate biomarker for pretreatment risk stratification, particularly when interpreted alongside established tumor-related predictors such as Ki-67 and HER2 status. The association appears especially relevant in the triple-negative subgroup, suggesting that patients with TNBC and low pretreatment serum albumin may warrant heightened multidisciplinary attention during NACT. Validation in larger, prospective, multicenter cohorts is needed before routine clinical implementation.
- Open Access
- 27 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 713
Association of Post-Neoadjuvant Chemotherapy MRI and 18F-FDG PET/CT Findings with Tumor Response and Prognosis in Breast Cancer
Accurate non-invasive prediction of pathological complete response (pCR) following neoadjuvant chemotherapy (NACT) in breast cancer (BC) remains challenging despite its established prognostic significance. Objective: We aimed to evaluate the prognostic utility of baseline and post-NACT magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting pCR and survival outcomes, focusing on molecular subtype-specific performance and post-NACT imaging discordance. Methods: In this multicenter study, we retrospectively analyzed 335 patients with BC who received NACT between 2015 and 2025. Baseline (pre-NACT) and post-NACT imaging assessments were performed using MRI and 18F-FDG PET/CT. Pathological response was graded using the Miller–Payne classification system. Multivariable logistic regression was applied to identify independent predictors of pCR, whereas survival outcomes were examined using Kaplan–Meier analysis and Cox regression. Results: The overall pCR rate was 41.2%. Post-NACT imaging demonstrated complete response in 58.7% of patients by 18F-FDG PET/CT and 43.6% by MRI, both significantly correlating with pCR (p < 0.001). Pre-NACT MRI tumor size showed predictive value exclusively in Luminal A/B HER2-negative disease (area under curve = 0.681; p = 0.013). Importantly, post-NACT discordance between MRI and 18F-FDG PET/CT-based tumor size assessments was an independent predictor of both mortality (hazard ratio, 1.03) and disease progression (hazard ratio, 1.01). Conclusions: Post-NACT MRI and 18F-FDG PET/CT findings correlate strongly with pCR achievement, whereas pre-NACT MRI tumor size predicts pCR only in hormone receptor-positive HER2-negative subtypes. Importantly, post-NACT imaging discordance independently predicted mortality and disease progression, suggesting that dual-modality imaging assessment may identify high-risk patients requiring intensified surveillance.
- 27 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 713
Open AccessAssociation of Post-Neoadjuvant Chemotherapy MRI and 18F-FDG PET/CT Findings with Tumor Response and Prognosis in Breast Cancer
Accurate non-invasive prediction of pathological complete response (pCR) following neoadjuvant chemotherapy (NACT) in breast cancer (BC) remains challenging despite its established prognostic significance. Objective: We aimed to evaluate the prognostic utility of baseline and post-NACT magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting pCR and survival outcomes, focusing on molecular subtype-specific performance and post-NACT imaging discordance. Methods: In this multicenter study, we retrospectively analyzed 335 patients with BC who received NACT between 2015 and 2025. Baseline (pre-NACT) and post-NACT imaging assessments were performed using MRI and 18F-FDG PET/CT. Pathological response was graded using the Miller–Payne classification system. Multivariable logistic regression was applied to identify independent predictors of pCR, whereas survival outcomes were examined using Kaplan–Meier analysis and Cox regression. Results: The overall pCR rate was 41.2%. Post-NACT imaging demonstrated complete response in 58.7% of patients by 18F-FDG PET/CT and 43.6% by MRI, both significantly correlating with pCR (p < 0.001). Pre-NACT MRI tumor size showed predictive value exclusively in Luminal A/B HER2-negative disease (area under curve = 0.681; p = 0.013). Importantly, post-NACT discordance between MRI and 18F-FDG PET/CT-based tumor size assessments was an independent predictor of both mortality (hazard ratio, 1.03) and disease progression (hazard ratio, 1.01). Conclusions: Post-NACT MRI and 18F-FDG PET/CT findings correlate strongly with pCR achievement, whereas pre-NACT MRI tumor size predicts pCR only in hormone receptor-positive HER2-negative subtypes. Importantly, post-NACT imaging discordance independently predicted mortality and disease progression, suggesting that dual-modality imaging assessment may identify high-risk patients requiring intensified surveillance.
- 16 April 2024
- Published by Springer Nature in Surgery Today
- Vol. 54 (9) , 1022-1030
Efficacy of sentinel lymph-node biopsy after neoadjuvant chemotherapy in clinically axilla node-negative patients
Purpose Breast cancer is the most common cancer in women. Developments in breast cancer treatment have extended the life expectancy of these patients, raising the issue of morbidity of breast cancer surgery, the major cause of which is axillary dissection. The aim of the present study was to establish the safety of sentinel node biopsy (SLNB) in patients with a clinically node-negative axilla after neoadjuvant chemotherapy (NACT). Methods We recorded demographic data, as well as the findings of physical examination, imaging, and pathology before and after NACT. SLNB with indocyanine green + isosulfan blue and axillary dissection were performed and the surgical and pathology findings were recorded. Results A sentinel lymph node was detected in 80 of 90 patients who underwent surgery. When ≥ three sentinel lymph nodes were removed as negative in the patient group with cN0 after treatment, we evaluated the axilla as being negative with an accuracy of 100%. Conclusions Axillary lymph-node dissection may not be necessary for patients with cNO confirmed by physical and radiological examination using positron emission tomography (PET) computed tomography (CT), and breast magnetic resonance imaging (MRI) after NACT, if ≥ three negative SLNB are removed. Further studies are needed to confirm our findings.
- 16 April 2024
- Published by Springer Nature in Surgery Today
- Vol. 54 (9) , 1022-1030
Efficacy of sentinel lymph-node biopsy after neoadjuvant chemotherapy in clinically axilla node-negative patients
Purpose Breast cancer is the most common cancer in women. Developments in breast cancer treatment have extended the life expectancy of these patients, raising the issue of morbidity of breast cancer surgery, the major cause of which is axillary dissection. The aim of the present study was to establish the safety of sentinel node biopsy (SLNB) in patients with a clinically node-negative axilla after neoadjuvant chemotherapy (NACT). Methods We recorded demographic data, as well as the findings of physical examination, imaging, and pathology before and after NACT. SLNB with indocyanine green + isosulfan blue and axillary dissection were performed and the surgical and pathology findings were recorded. Results A sentinel lymph node was detected in 80 of 90 patients who underwent surgery. When ≥ three sentinel lymph nodes were removed as negative in the patient group with cN0 after treatment, we evaluated the axilla as being negative with an accuracy of 100%. Conclusions Axillary lymph-node dissection may not be necessary for patients with cNO confirmed by physical and radiological examination using positron emission tomography (PET) computed tomography (CT), and breast magnetic resonance imaging (MRI) after NACT, if ≥ three negative SLNB are removed. Further studies are needed to confirm our findings.